Hims & Hers Health (NYSE:HIMS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health (NYSE:HIMS) in a report issued on Friday. The firm set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 18.70% from the stock’s current price.

A number of other brokerages have also issued reports on HIMS. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research note on Monday, March 16th. TD Cowen cut their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Truist Financial reissued a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $32.53.

Hims & Hers Health Trading Up 1.6%

Shares of Hims & Hers Health stock opened at $29.49 on Friday. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of 57.82, a PEG ratio of 2.75 and a beta of 2.32. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a 50 day moving average of $20.70 and a 200 day moving average of $31.71.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same period in the previous year, the firm earned $0.11 earnings per share. Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health will post 0.61 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the transaction, the chief operating officer owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares of the company’s stock, valued at $216,086.88. This represents a 38.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 204,857 shares of company stock worth $5,285,706. Company insiders own 13.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the period. Capital World Investors boosted its stake in Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares in the last quarter. Farallon Capital Management LLC grew its position in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp lifted its holdings in Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after purchasing an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after acquiring an additional 608,950 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded Eli Lilly tie‑up — HIMS said clinicians on its platform can now connect patients to Eli Lilly self‑pay pricing and fulfillment (Zepbound vials, KwikPen, Foundayo via LillyDirect), driving a near‑term revenue pathway for weight‑loss prescriptions and sparking a prior ~7% jump in the stock. Article Title
• Positive Sentiment: New product expansion into menopause care — HIMS is adding perimenopause/menopause treatment options (including estrogen patches) to its telehealth platform to capture rising U.S. demand, expanding addressable market and recurring care use cases. Article Title
• Positive Sentiment: Regulatory/pipeline momentum — An FDA Pharmacy Compounding Advisory Committee review of several peptides has been scheduled (July), which market participants view as a potential tailwind for HIMS’ peptide ambitions and helped recent sentiment. Article Title
• Neutral Sentiment: Analyst update — Bank of America raised its price target from $30 to $32 but kept a “neutral” rating, signaling modest upside without changing conviction. Article Title
• Neutral Sentiment: Independent Rx fills & sector flows — News roundups note increased independent Rx fills and broad interest in telehealth/weight‑loss plays; sector rotation and flow can amplify HIMS’ volatility even when company‑specific news is mixed. Article Title
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe sold 19,645 shares and director/insider Soleil Boughton sold 9,463 shares under 10b5‑1 plans; sizeable insider exits are pressuring near‑term sentiment despite being pre‑arranged. Okupe SEC Filing Boughton SEC Filing
• Negative Sentiment: Competitive risk — Large entrants (notably Amazon’s GLP‑1/weight‑loss efforts) and other well‑capitalized competitors raise concerns about pricing pressure and customer share loss in the high‑value weight‑loss channel. Article Title

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.